Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:ATCCode |
M09AX10
|
| gptkbp:CASNumber |
2098261-92-6
|
| gptkbp:developer |
gptkb:Alnylam_Pharmaceuticals
|
| gptkbp:drugClass |
gptkb:small_interfering_RNA_(siRNA)
|
| gptkbp:EMA_approval_date |
2020-11-19
|
| gptkbp:FDAApproved |
2020-11-23
|
| gptkbp:form |
solution for injection
|
| gptkbp:genericName |
gptkb:lumasiran
|
| https://www.w3.org/2000/01/rdf-schema#label |
OXLUMO
|
| gptkbp:indication |
gptkb:primary_hyperoxaluria_type_1
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:RNA_interference
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:target |
gptkb:hydroxyacid_oxidase_1_(HAO1)_mRNA
|
| gptkbp:UNII |
6Z1Y2V4S2E
|
| gptkbp:bfsParent |
gptkb:NASDAQ:_ALNY
|
| gptkbp:bfsLayer |
7
|